Physician profile
Eric S Lippman
NPI 1891722765
$3,631.04
in general payments reported to CMS, 2019-2025
18 companies · $774 in 2025
The $774 reported for 2025 was more than what 85% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $263 · 2021: $314 · 2022: $535 · 2023: $726 · 2024: $622 · 2025: $774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,121.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,471.89 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $662.00 | 2020-2025 | |
| Amgen INC. | $420.74 | 2021-2025 | Evenity, Prolia, Prolia |
| Ucb, INC. | $301.34 | 2021-2025 | Bimzelx, Cimzia |
| Neurocrine Biosciences, INC. | $123.40 | 2023 | Ingrezza |
| Radius Health, INC. | $100.66 | 2024-2025 | Tymlos |
| Aurinia Pharma U.S., INC. | $94.17 | 2022-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $80.35 | 2023-2024 | Strensiq |
| Bioventus LLC | $60.52 | 2021-2024 | Gelsyn-3 |
| Glaxosmithkline, LLC. | $56.03 | 2020-2021 | |
| Ipsen Biopharmaceuticals, INC | $51.26 | 2019-2021 | |
| Fidia Pharma USA INC. | $46.12 | 2019-2022 | |
| Allergan, INC. | $41.49 | 2019-2020 | |
| Depuy Synthes Sales INC. | $39.40 | 2019-2024 | Orthovisc, Monovisc |
| Fresenius Kabi USA, LLC | $32.80 | 2023 | Idacio |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $20.96 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $13.97 | 2021 | |
| Sandoz INC. | $13.94 | 2024 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Lippman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.